Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma

Abstract

The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for combination therapy a lower dose seems reasonable.